Evidence map›Paper›PMID 33684115›Full record

ArticlePLoS neglected tropical diseases2021

Control of cystic echinococcosis in the Middle Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment in dogs.

Fatimaezzahra Amarir, Abdelkbir Rhalem, Abderrahim Sadak, Marianne Raes, Mohamed Oukessou, Aouatif Saadi, Mohammed Bouslikhane, Charles G Gauci, Marshall W Lightowlers, Nathalie Kirschvink and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. The RecombinantFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Fatimaezzahra AmarirLaboratory of Parasitology, Department of Pathology and Veterinary Public Health, Hassan II Agronomy and Veterinary Institute (IAV), Rabat, Morocco.ORCID 0000-0003-3367-8435
Abdelkbir RhalemLaboratory of Parasitology, Department of Pathology and Veterinary Public Health, Hassan II Agronomy and Veterinary Institute (IAV), Rabat, Morocco.
Abderrahim SadakLaboratory of Zoology and General Biology, Parasitological and Ecological Unit, Faculty of Sciences, Mohammed V University, Rabat, Morocco.ORCID 0000-0001-8312-4233
Marianne RaesIntegrated Veterinary Research Unit, Department of Veterinary Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Belgium.ORCID 0000-0002-4083-7521
Mohamed OukessouUnit of Physiology and Therapeutics, Department of Veterinary Biological and Pharmaceutical Sciences, Hassan II Agronomic and Veterinary Institute, Rabat, Morocco.
Aouatif SaadiLaboratory of Parasitology, Department of Pathology and Veterinary Public Health, Hassan II Agronomy and Veterinary Institute (IAV), Rabat, Morocco.
Mohammed BouslikhaneLaboratory of Parasitology, Department of Pathology and Veterinary Public Health, Hassan II Agronomy and Veterinary Institute (IAV), Rabat, Morocco.
Charles G GauciFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Australia.ORCID 0000-0001-5097-2164
Marshall W LightowlersFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Australia.
Nathalie KirschvinkIntegrated Veterinary Research Unit, Department of Veterinary Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Belgium.ORCID 0000-0003-1788-4212
Tanguy MarcottyIntegrated Veterinary Research Unit, Department of Veterinary Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Belgium.
Institut Agronomique et Vétérinaire Hassan II · MAUniversity of Namur · BEMohammed V University · MAThe University of Melbourne · AUUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic echinococcosis (CE) is an important cause of human morbidity and mortality worldwide, particularly in Morocco and other North African countries. METHODOLOGY/PRINCIPAL

findingsWe investigated the potential of three strategies to reduce Echinococcus granulosus transmission: (1) 4-monthly treatment of dogs with praziquantel, (2) vaccination of sheep with the EG95 vaccine and (3) a combination of both measures. These measures were implemented during four consecutive years in different areas of the Middle Atlas Mountains in Morocco. The outcome of the interventions was assessed through hydatid cyst (viable and non-viable) counts in liver and lungs using necropsy or in vivo ultrasound examination of the liver. A total of 402 lambs were recruited for annual vaccination with the EG95 anti-E. granulosus vaccine and 395 similar lambs were selected as non-vaccinated controls. At approximately four years of age the relative risk (estimated as odds ratio) for vaccinated sheep to have viable hydatid cysts compared with non-vaccinated controls was 3% (9.37% of the vaccinated sheep were found infected while 72.82% of the controls were infected; p = 0.002). The number of viable cysts in vaccinated animals was reduced by approximately 97% (mean counts were 0.28 and 9.18 respectively; p<0.001). An average of 595 owned dogs received 4-monthly treatment during the 44 months trial, corresponding to 91% of the owned dog population. Approximately, 5% of them were examined for E. granulosus adult worms by arecoline purge or eggs in feces (confirmed by PCR). The proportion of infected dogs significantly decreased after treatment (12% versus 35%; p<0.001). Post-treatment incidence of re-infestation corresponded to a monthly risk of 4% (95% CI: 3-6%). Treatment of owned dogs on a 4-monthly basis did not reduce the level of transmission of E. granulosus to sheep, nor did it enhance the level of control generated by vaccination of sheep with EG95, possibly because of unowned dogs and wild canids were not treated. CONCLUSIONS/SIGNIFICANCE: These data suggest that vaccination of sheep with EG95 has the potential to reduce the level of CE in Morocco and in other parts of the world with similar transmission dynamics. Under the epidemiological circumstances existing in the trial area, 4-monthly treatment of owned dogs with praziquantel was insufficient to have a major impact of E. granulosus transmission to sheep.

Indexed as

AnimalsAntigens, HelminthDog DiseasesDogsEchinococcosisHelminth ProteinsMoroccoPraziquantelSheepSheep DiseasesVaccinationAntigens, HelminthEG95 protein, Echinococcus granulosusHelminth ProteinsPraziquantel

Identifiers

PMID33684115
PMCPMC7971873
OpenAlexW3134330211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.